Management members

Lynne Powell

CEO

Ms. Powell has more than 25 years’ experience in the biopharmaceutical/ biotechnology industry.  Prior to DRGT she served as Chief Commercial Officer at BioCryst, an emerging biotechnology company focused on commercializing innovative small molecules. Before this, she was Senior Vice President, North America, at CSL Behring.  Throughout her 17-year career at CSL Behring, she assumed increasing responsibilities within the R&D and commercial functions of the organization. Lynne has significant global experience serving as Vice President, Global Commercial Development and Head of Business Development & European Marketing, Head of Project and Portfolio Management and Head of Clinical Research. Ms. Powell also held positions within Glaxo Wellcome’s commercial strategy and clinical research organizations.

Lyenne Powell

Dr. Kevin P. Malobisky

Chief Regulatory and Strategic Operations Officer

Dr. Malobisky brings over 30 years of executive leadership and global drug development to DRGT USA.  Most recently, Dr. Malobisky was the Senior Vice President, Global Regulatory Affairs, Quality, and Compliance at Achillion Pharmaceuticals where he led the successful regulatory and quality development of danicopan, for the treatment of the rare diseases paroxysmal nocturnal hemoglobinuria (PNH) and C3 Glomerulopathy (C3G).  Under his leadership, danicopan was granted Breakthrough Therapy Designation by the Food and Drug Administration and PRIME designation by the European Medicines Agency.  Previously, Dr. Malobisky was the Senior Vice President, Global Regulatory Affairs, Quality, and Pharmacovigilance at Karyopharm Therapeutics where he led their first successful New Drug Application submission for XPOVIO ® (selinexor) tablets for the treatment of adult patients with relapsed or refractory multiple myeloma. Previously, Dr. Malobisky was the Global Head of Regulatory Affairs and Quality at Zafgen, a biotechnology company focused on the development of novel small molecules for the treatment of Prader-Willi Syndrome, a rare pediatric disease.  In addition to his experience in rare disease and biotechnology, Dr. Malobisky has also held positions of increasing responsibility at Sanofi, Roche Molecular Systems, and Hoffmann-LaRoche.   

After earning his Bachelor of Science degree in Microbiology from Penn State University, Dr. Malobisky earned his Master of Science degree in Regulatory Affairs and Quality Assurance from Temple University School of Pharmacy and his Doctor of Philosophy (Ph.D.) with distinction in Organization and Management from Capella University School of Business and Technology.  Dr. Malobisky is also Regulatory Affairs Certified (RAC). 


Dr. Elizabeth Manning Duus

Executive Director, Clinical Development, DRGT  USA

Dr. Duus brings 13 years of clinical research experience in the biopharmaceutical industry to DRGT USA. Most recently, she served as Senior Director, Clinical Research & Strategy at Helsinn Therapeutics (U.S.), Inc.  Over the past 8 years at Helsinn, Dr. Duus has led the clinical strategy for oncology-related compounds in development, contributed to global regulatory engagements, supported clinical operations and biostatistics, managed medical writing activities, and oversaw investigator-initiated and collaborative studies in the US. She has also held positions of increasing responsibility at Akros Pharma Inc and Avantix Laboratories.  After receiving an undergraduate degree in biology from the University of Delaware, Dr. Duus earned her PhD in pharmacology and molecular sciences from the Johns Hopkins University School of Medicine.



Dominic P. Capone

Senior Director, Clinical Development, DRGT  USA

Mr. Capone brings 24 years of clinical operations and clinical research experience in the biopharmaceutical industry to DRGT USA.  Most recently, he served as Senior Director Clinical Operations & Program Management at Antares Pharma, Inc.  Over the past 9 years Dominic has successfully led numerous products through the 505b2 pathway from IND to NDA submission.  Managing deliverables from multiple disciplines including Device, CMC, Clinical Research, and Regulatory.  Dominic also managed all aspects of clinical trials, Phase 1 thru Phase 3, including clinical operations, data management, and clinical supplies management.  He previously held positions in clinical operations and clinical supplies management at Akros Pharma Inc and Omnicare Pharmaceuticals Inc.  Prior to a career in the pharmaceutical industry Dominic served honorably in the United States Air Force as an Aerovac Medical Technician supporting military and humanitarian missions around the world.

Hristos Glavinas

Chief Scientific Officer

Dr. Glavinas is the Chief Scientific Officer  at NanGenex. Previously he held the position of Director of Pharnaceutical Development. Before joining the DRGT Team he served as  Principal Scientist, Head of Research and Development at Solvo Biotechnology. Prior he worked as visiting scientist at the Children’s Hospital Medical Center, Cincinnati, OH, USA. He completed his PhD studies in molecular biology at Albert Szent-Györgyi Medical University, Szeged, Hungary. He is the author of 27 peer reviewed research papers and presented his work at numerous international conferences. 


Katalin Ferenczi

Managing Director

Mrs. Ferenczi graduated as a biomedical engineer at University of Miami. After returning to Budapest, for a short period of time, she worked at Genpact, a formerly GE owned company, that has established itself as one of Europe’s business services and technology solutions providers. Between 2006 and 2010 she held a senior business development position at SOLVO Biotechnology and was responsible for the European sales operation of the company. She joined NanGenex- Member of the Druggability Technologies Group (DRGT) in 2010 and led its business development operation. In 2013 Mrs. Ferenczi took on the Managing Director position and helped the company to transition from being a simple service provider to becoming a true pharmaceutical company. 

Katalin Ferenczi

Genovéva Filipcsei, PhD

Chief IP Officer

Dr. Filipcsei has an MSc in colloid chemistry and a PhD in chemistry. She joined the DRGT Team in 2008. Genovéva is the former CSO of NanGenex. Currently she holds the position of Chief IP Officer. Previously, she served as a senior lecturer at Budapest University of Technology and Economics at the Faculty of Chemical engineering and bioengineering. She held a postdoctoral fellowship of Katholieke Universiteit Leuven and a research fellowship of Suzuki Foundation at National Institute of Advanced Industrial Science and Technology (AIST), Research Centre of Advanced Bionics Bio-Nanomaterials Team in Tsukuba. She received the Bolyai plaquette in 2007 and the Polanyi Price of Hungarian Academy of Sciences in 2009. Dr. Filipcsei was the winner of the Young Inventor of 2005 award in Hungary. She is the co-author of 44 publications in international journals, 25 patent applications, 12 international lectures and 45 conference posters. 

Dr. Genovéva Filipcsei